{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009483","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.857620+00:00","generated_at":"2026-06-17T18:27:32.182974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement","bullets":["Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.","Cash, equivalents and investments $245.2M at Dec 31, 2022, vs $319.7M year earlier.","Recorded $10M legal settlement expense for securities class action; subject to court approval.","Targeting LIFT-AD Phase 2/3 enrollment completion mid-2023, topline data early 2024.","ATH-1105 (ALS) IND-enabling studies ongoing; Phase 1 expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009483","json":"https://secwatch.observer/filing/0000950170-23-009483.json","markdown":"https://secwatch.observer/filing/0000950170-23-009483.md","text":"https://secwatch.observer/filing/0000950170-23-009483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/0000950170-23-009483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/atha-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:27:32.182974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f945c7cf41d7c7a911c64c26056bf762e2bd0823","claim":"LeonaBio, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/0000950170-23-009483-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}